Back Pain in Volunteers After Epidural Anesthesia With Chloroprocaine
To the Editor:
I found the recent report by Hynson et al. (1) very interesting. I frequently use 2% and 3% 2-chloroprocaine in my practice while performing diagnostic and therapeutic anesthetic blocks for patients in chronic pain.
I also have seen severe back pain and muscle spasm after these blocks but my experience would not implicate ethylenediaminetetraacetic (NaEDTA) acid as the precipitating agent of this phenomenon as was suggested. I frequently use 2% 2-chloroprocaine in performing my blocks and only rarely have a problem despite the use of relatively large volumes (20-60 mL injected in approximately 5-mL increments), whereas on the few occasions I have needed to progress to 3% 2-chloroprocaine, there seems to be a high incidence of muscle spasm and severe pain as the block wears off-despite the use of smaller volumes overall. As NaEDTA is present in both formulations in the same concentration, based on my own experience it is unlikely that it is the sole source of this phenomenon. However, I agree it is a real phenomenon and something seen only rarely with the previous formulation of this drug. In Response:
In our discussion, we suggested several potential etiologies for back pain after epidural chloroprocaine administration, but did not endorse one in particular. The possible causes listed included the theory proposed by Fibuch and Opper (1) that pain is caused by EDTA. In support of this etiology, Wang et al. recently reported that hourly lumbar epidural injections of 0.1 mL of 0.1% EDTA in rats result in tetanic contractions of the lower extremities and focal neuropathologic changes when the total dose exceeded 0.1 mg (2). For comparison, the total dose of disodium EDTA after a 35-mL lumbar epidural injection of Nesacaine-MPF in humans would be 3.5 mg. (The concentration of disodium EDTA in Nesacaine-MPF is 0.011% .) Although not definitely implicating EDTA as the causative agent, this study suggests that further investigation of its neurophysiologic effects, neurotoxicity, and myotoxicity is warranted. Dr. Day's personal observations of back pain after the use of chloroprocaine in the pain clinic are interesting. One consistency in the published reports, as well as the experience of Dr. Day and other clinicians with whom we have spoken, is that this characteristic back pain after 3% chloroprocaine has been observed primarily in patients treated on an outpatient basis. The recent emergence of this problem could in fact be unrelated to the introduction of Nesacaine-MPF. Rather, the increased number of outpatients receiving epidural blocks in recent years may simply have helped to uncover the association of back pain with epidural chloroprocaine. James M. Hynson, MD Daniel I. Sessler, MD
